Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE In the multivariate analysis, negative p16 immunostaining was associated with a worse overall survival together with advanced FIGO stage and lymph node metastases. 31492932

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE Mts1 was highly expressed in patients with thyroid cancer and high Mts1 levels were related to poor prognoses such as lymph node metastasis. 31467231

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE Negative P16 expression was significantly associated with NSCLC with lymph node metastasis (p=0.025). 31662516

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE Predictive value of computed tomography in identifying extracapsular spread of cervical lymph node metastases in p16 positive oropharyngeal squamous cell carcinoma. 30973213

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE A total of 28 studies with 2612 nasopharynx cancer patients were included in the meta-analysis. p16 protein expression was significantly associated with the risk, lymph node metastasis, TNM-stage (tumor-node-metastasis), distant metastasis, and T stage of nasopharynx cancer (Risk, OR = 17.82, 95% CI = 11.20-28.35; Lymph node metastasis, OR = 2.11, 95% CI = 1.42-3.14; TNM-stage, OR = 2.25, 95% CI = 1.54-3.28; Distant metastasis, OR = 3.43, 95% CI = 1.55-7.58; T-stage, OR = 1.72, 95% CI = 1.27-2.33). 30882625

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE We evaluate CD274 (PD-L1), CDKN2A (p16), tumor protein p53 (TP53), and epidermal growth factor receptor (EGFR) immunoexpression in primary tumors, recurrences and lymph node metastases and its correlations with prognosis and HPV status. 31844270

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE FHIT was related to HCC tumor-node-metastasis (TNM) staging, the differentiation degree in Edmondson-Steiner grading, lymph node metastasis and portal vein thrombosis (P<0.05 in all comparisons), whereas, p16 was associated with tumor size and the differentiation degree in Edmondson-Steiner grading (P<0.05 in all comparisons). 30655841

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 PosttranslationalModification BEFREE Moreover, CDKN2A methylation was significantly associated with gender (OR = 1.34; P < 0.05) and lymph node metastasis (OR = 2.32; P < 0.01). 30355925

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE Furthermore, p16 protein overexpression was significantly associated with the Dukes stage, lymph node metastasis, tumor location, and Tumor Lymph Node Metastasis-stage of colorectal cancer. 29561443

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE Comparing HPV DNA status with p16 we found that 21 primary tumors and lymph node metastases were HPV positive (61.8%) and seven primary tumors and lymph node metastases were HPV negative (20.6%). 28758552

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE The positive rate of p16 protein expression in ovarian cancer tissue of patients with lymph node metastasis was significantly decreased compared with that of patients without lymph node metastasis. 28943963

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE DAPK1 level in the tumour was significantly higher in females than in males, the MGMT and p16 levels were lower in the tumours with lymph node metastasis (N1 + N2) than in N0 samples. 28421310

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE The p16INK4a overexpression was found to correlate significantly with the lower International Federation of Gynecology and Obstetrics stage (I+II vs III+IV; OR = 0.60, 95%CI: 0.41-0.86, P = 0.006), negative lymph node metastasis(negative vs positive; OR = 0.61, 95%CI: 0.39-0.95, P = 0.029), patient's age <55 (OR = 0.54, 95%CI: 0.31-0.96, P = 0.034), human papillomavirus-positive status (OR = 0.01, 95%CI: 0.00-0.11, P<0.001), and higher overall survival (RR = 0.53, 95%CI = 0.35-0.80, P = 0.003). 27031618

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE No significant correlation was seen with history of abnormal sexual habits, but p16 expression was significantly correlated in cases with multiple sexual partners (P = 0.003), with increasing histological grade (P = 0.045) and in cases with lymph node metastasis (P = 0.03). 27072243

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE One hundred forty-three patients with cHNSCC lymph node metastases involving the parotid gland were evaluated for p16 expression by immunohistochemistry. 26881928

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE Multivariate analysis has demonstrated that lymph node metastasis (HR 1-2.74, 95 % CI 1.50-5.02, p = 0.019), tumor grade (HR 1-2.80, 95 % CI 1.33-5.90, p = 0.007) and p16(ink4a)-overexpression (HR 1-2.11, 95 % CI 1.13-3.95, p = 0.001) are independent prognostic factors. 27411473

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE Moreover, p16 protein was associated with CIN grade and lymph node metastases in cervical cancer (all P<0.05); survivin protein was also related with clinical stages, CIN grade and lymph node metastases (all P<0.05); the p16 and survivin expressions were positively correlated with cervical cancer (r=0.854, P<0.001), and associated with poor prognosis of cervical cancer. 25910412

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE Kaplan-Meier survival analysis showed that tumor size (P = 0.031), lymph node metastasis (P < 0.001), pathological stage (P < 0.001), P53(Mut) protein expression (P = 0.038), and loss of p16 or Smad4 expression (P < 0.001) were significantly associated with shorter overall survival(OS), whereas multivariate analysis indicated that lymph node metastasis (P = 0.014) and loss of p16 or Smad4 expression (P < 0.001) were independent prognostic factors. 25890228

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE Thus, patients with P16(ink4a) negative penile cancer, particularly those with lymph node metastases, may warrant closer observation after surgery. 25261804

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE The results showed that the membrane weighted index of β-catenin was inversely correlated with p16 positivity (P < .001) and lymph node metastasis (P = .026), whereas nuclear staining of β-catenin was associated with p16-positive OPSCC (P < .001). 25209444

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 AlteredExpression BEFREE JARID1B/KDM5B protein expression was positively associated with T grade, Bloom and Richardson (B&R) score and axillary lymph node metastasis (P < 0.05). p16 protein expression was negatively associated with T grade, B&R score, and axillary lymph node metastasis (P < 0.05). 26125737

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 PosttranslationalModification BEFREE Furthermore, we observed significant associations of p16 promoter methylation with TNM stage, histologic grade, invasive grade, lymph node metastasis of GC (TNM stage: OR = 3.60, 95% CI: 2.17-5.98, P < 0.001; Histologic grade: OR = 2.63, 95% CI: 1.55-4.45, P < 0.001; Invasive grade: OR = 3.44, 95% CI: 1.68-7.06, P = 0.001; Lymph node metastasis: OR = 2.68, 95% CI: 1.66-4.32, P < 0.001; respectively). 24610350

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 PosttranslationalModification BEFREE The frequency of p16 methylation was significantly higher in GC tissues (85.9%; 79/92) than that in paired PCHNTs (12.0%; 11/92) (P<0.0001). p16 methylation correlated closely with lymph node metastasis, peritoneal metastasis, TNM stage, et al (all P<0.05). 24817951

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 PosttranslationalModification BEFREE Our meta-analysis results revealed that p16 promoter methylation was associated with pathological characteristics of CRC (tumor, nodes, metastasis stage: OR=1.55, 95% CI: 1.14-2.13, p=0.006; lymph node metastasis: OR=2.40, 95% CI: 1.37-4.19, p=0.002; histologic grade: OR=2.72, 95% CI: 1.63-4.54, p<0.001; Dukes stage: OR=2.06, 95% CI: 1.57-2.71, p=0.002; tumor size: OR=1.99, 95% CI: 1.03-3.85, p=0.041; location: OR=2.49, 95% CI: 1.95-3.18, p<0.001, respectively). 24979649

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
Secondary malignant neoplasm of lymph node
0.100 Biomarker BEFREE Kaplan-Meier survival analysis showed that lymph node metastasis (P = 0.001), lymphatic invasion (P = 0.008), the tumor (T) factor (T3 vs. T1/T2, P = 0.004), loss of p16 immunolabeling (P = 0.029), and loss of Smad4/Dpc4 immunolabeling (P < 0.001) were significantly associated with shorter overall survival. 23470568

2013